News
MTSR
70.50
0.00%
0.00
Pfizer Sees Slower 2026 Growth Despite Pipeline Push, Cost Cuts
Benzinga · 12/16/2025 14:28
Can AI Drive Peloton's Comeback?
The Motley Fool · 11/18/2025 19:23
Down 55%, Should You Buy the Dip on Pfizer?
The Motley Fool · 11/17/2025 09:35
Is Pfizer Stock a Buy After This $10 Billion Acquisition?
The Motley Fool · 11/15/2025 10:45
Deal Dispatch: Warner Bros., Bill.com, C3 AI—Key Auctions And Buyouts Shake The Market
Benzinga · 11/14/2025 20:34
Ozempic Maker Novo Nordisk Faces Board Shakeup
Benzinga · 11/14/2025 14:12
Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks Delivering High-Dividend Yields
Benzinga · 11/14/2025 12:02
Why Is Everyone Talking About Novo Nordisk Stock?
The Motley Fool · 11/14/2025 11:15
Metsera, Inc. Completes Merger and Restructures Leadership
TipRanks · 11/13/2025 22:32
*News On Metsera Inc. (MTSR) Now Under PFE
Dow Jones · 11/13/2025 22:09
Metsera Inc. Completes Merger and Delists from Nasdaq
Reuters · 11/13/2025 21:53
Pfizer Stock (PFE) Rises as Metsera Shareholders Approve $10B Acquisition Offer
TipRanks · 11/13/2025 17:07
Pfizer Completes Acquisition Of All Outstanding Common Shares Of Metsera For $65.60 Per Share In Cash
Benzinga · 11/13/2025 16:30
Pfizer Seeks To Exit BioNTech Investment After Lucrative Covid Vaccine Run
Benzinga · 11/13/2025 16:10
'Not been pretty': Novo Nordisk faces rare shareholder rebuke over board shake-up
Reuters · 11/13/2025 15:20
Metsera shareholders vote to approve $10B sale to Pfizer
Seeking Alpha · 11/13/2025 14:58
BUZZ-Novo Nordisk falls after Metsera shareholders vote for Pfizer's offer
Reuters · 11/13/2025 14:25
Mangoceuticals Stock (MGRX) Soars on Deal to Sell Obesity Drugs for Eli Lilly, Novo Nordisk
TipRanks · 11/13/2025 14:10
METSERA INSPECTOR OF ELECTION DECLARES MERGER AGREEMENT PROPOSAL HAS BEEN ADOPTED BY MAJORITY OF SHAREHOLDERS ENTITLED TO VOTE, AS PER PRELIMINARY COUNT
Reuters · 11/13/2025 14:09
METSERA SHAREHOLDERS VOTE IN FAVOR OF PROPOSED ACQUISITION BY PFIZER FOR UP TO $10 BILLION, AS PER PRELIMINARY COUNT
Reuters · 11/13/2025 14:09
More
Webull provides a variety of real-time MTSR stock news. You can receive the latest news about Metsera through multiple platforms. This information may help you make smarter investment decisions.
About MTSR
Metsera, Inc. is a clinical-stage biopharmaceutical company, which is developing a broad portfolio of oral and injectable incretin, non-incretin and combination therapies. The Company uses its proprietary MINT peptide library of nutrient stimulated hormone (NuSH) analog peptides alongside its half-life augmentation by lipid optimization (HALO) half-life extending platform and its MOMENTUM oral NuSH analog peptide delivery platform to deliver differentiated product candidates. Its product pipeline includes MET-097i, MET-233i, MET-233i + MET-097i, MET-097o/MET-224o, MET-002o, MET-034i, MET-067i, and MET-815i. The Company's additional pipeline includes MET-815i, MET-AMYo, MET-034i, MET-067i and MET-PYYi. MET-097i, its advanced product candidate, is a fully biased, monthly, subcutaneously injectable ultra-long acting GLP-1 RA. MET-233i is a subcutaneously injectable ultra-long-acting amylin analog, with enhanced solubility and miscibility with its other NuSH analog peptides.